University of Tennessee Research Foundation

Other

University of Utah Research Foundation

University of Memphis

Gabor G Tigyi

Duane Douglas Miller

Tamas Virag

Renukadevi Patil

Michelle D Walker

Ryoko Tsukahara

Gangadhar G Durgam

James T Dalton

Glenn D Prestwich

David John Fischer

Daniel Lee Baker

Guanghui Yang

Abby Louise Parrill-Baker

Honglu Zhang

Xiaoyu Xu

Souvik Banerjee

Joanna Gajewiak

Vineet M Sardar

Don B Elrod

Huiping Xu

Dean Wang

Karoly Liliom

James Fells

Nora Nusser

Guowei Jiang

Renuka Gupte

Anjaparavanda Naren

Gangadhar Durgam

Chunying Li

Leonard Johnson

Wenlin Deng

The present disclosure provides novel ATX inhibitors, and pharmaceutical compositions comprising said inhibitors, as well as methods of treatment comprising administration of said inhibitors.

Autotaxin inhibitors

Disclosed are compounds effective for inhibiting cellular apoptosis and for protecting cells and tissues from the apoptotic effects of chemotherapeutic agents and/or ionizing radiation. Compounds of the invention act as agonists of the LPAreceptor. Compounds of the invention comprise non-lipid benzoic acid derivatives.

[object Object]

Described herein is the synthesis and pharmacology of a series of &#x3b1;-substituted methylene phosphonate analogs, in which the &#x3b1;-CHmoiety is replaced with CHCl or CHBr.

Alpha-chloro and alpha-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof

Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin.

Inhibitors of autotaxin

Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

LPA receptor agonists and antagonists and methods of use

The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

Growing community of inventors

Memphis, TN, United States of America

Gabor G Tigyi